annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 13G Clinical relevance of TNM staging system according to breast cancer (BC)
subtypes. (Abstract #632)
Y. Park, S. Lee, J. Kong, E. Cho, Y. Choi, J. Lee, S. Nam, J. Yang, J. Ahn, Y. Im
Brd. 13H Can tumor biomarkers predict response to neoadjuvant anthracycline/taxane
chemotherapy in LABC? (Abstract #633)
J. F. Hilton, J. I. Weberpals, I. Lorimer, M. Nabavi, F. Kanji, S. Hopkins,
S. Robertson, M. Daneshmand, S. Verma
Brd. 14A Prognostic value of CD44s in the NCI randomized trial on breast
conservation with 25-year follow-up. (Abstract #634)
T. D. Dan, D. Ly, S. M. Hewitt, B. P. Soule, A. S. Nowacki, J. Gillespie,
D. N. Danforth, J. B. Mitchell, K. A. Camphausen, N. L. Simone
Brd. 14B Predictive role of [18F]FDG-PET early evaluation in patients (pts) undergoing
preoperative chemotherapy (PCT) for breast cancer (BC). (Abstract #635)
A. Martoni, C. Zamagni, S. Quercia, M. Rosati, N. Cacciari, A. Bernardi, M.
Castellucci, D. Santini, M. Taffurelli
Brd. 14C The expression patterns of STAT-3, phosphorylated STAT-3, P38 MAPkinase,
and phosphorylated P38 MAP-kinase in triple-negative breast
cancers and their prognostic significance. (Abstract #636)
E. Yaman, I. I. Gonul, S. Buyukberber, U. Coskun, D. Yamac, A. Sevinc, F. Dane,
A. Uner, B. Ozturk, A. O. Kaya
Brd. 14D Use of trastuzumab associated with cisplatin and vinorelbine followed by
docetaxel as a neoadjuvant regimen for patients with HER2-positive breast
cancer. (Abstract #637)
G. Carillio, R. Aiello, A. Mazzola, M. Ali’, G. Scandurra, E. Taibi, M. Chiarenza,
G. Fallica, F. Caruso, M. Caruso, Humanitas Centro Catanese di Oncologia
Brd. 14E Twenty-year results of alternating radiotherapy and chemotherapy in
nonmetastatic inflammatory breast cancer. (Abstract #638)
E. Lima Pessoa, A. Dunant, S. Heymann, S. Delaloge, M. Spielmann, C. Uzan,
M. Mathieu, R. Arriagada, H. Marsiglia, C. Bourgier
Brd. 14F Early therapeutic intervention based on blood tumor markers (TMs) in
patients with primary breast cancer (PBC). (Abstract #639)
J. F. Robertson, J. Mathew, P. Prinsloo, A. Agrawal, E. Gutteridge, E. Merenah,
K. Cheung
Brd. 14G Independent comparison of three mathematical models for predicting the
risk of additional nodal metastases after positive sentinel lymph node biopsy
in early breast cancer. (Abstract #640)
Y. Moghaddam, M. Falzon, L. Fulford, N. R. Williams, M. R. Keshtgar
Brd. 14H Composite and component expression score correlations in ER-positive
breast cancer. (Abstract #641)
A. M. Wang, C. Santini, U. Vogt, R. Lagier, D. Kemming, C. Rowland, S. Kwok,
S. Broder, J. Sninsky, B. Brandt
Brd. 15A Comparison of a novel molecular assay with touch imprint and permanent
histology of sentinel lymph nodes in early-stage breast cancer. (Abstract
#642)
S. Saha, S. Sirop, B. Chakravarty, D. Wiese, M. Soni, A. Singla, E. Quiachon,
W. Liu, A. Ahsan, J. Badin
Brd. 15B Low adherence to long-term adjuvant endocrine therapy in breast cancer
women age 40 or younger. (Abstract #643)
D. Rey-Herin, A. D. Bouhnik, S. Cortaredona, V. Seror, M. K. Bendiane, Y. Odadia,
P. Viens
Brd. 15C Effect of preoperative concomitant chemoradiotherapy in chemotherapyrefractory
breast cancer on feasibility of curative surgery and pathologic
tumor response. (Abstract #644)
I. Ghorbel, S. Heymann, S. Delaloge, A. Belaid, F. Azoury, C. Mazouni,
C. Balleyguier, P. Vielh, H. Marsiglia, C. Bourgier
154